MedTech & BioTools Cohort
From Devices, Diagnostics & Enabling Technologies
To Investable Firms.
This MedTech & BioTools cohort supports CEOs building
medical devices, diagnostics, and enabling
technologies powering life sciences innovation.
Technical innovation may be strong, but
companies often struggle navigating commercialization,
reimbursement, manufacturing, and investor readiness.
CEO360 helps CEOs build
companies investors trust to scale.
Companies often serve healthcare providers,
pharmaceutical
companies, or research institutions.
CEO360 MedTech - BioTools Cohort
The MedTech & BioTools
Cohort Serves
Companies Developing:
- Medical devices
- Diagnostic platforms
- Research and clinical tools
- Enabling life science technologies
- Device and tools companies preparing for scale
- Seed through Series A companies
- CEOs preparing for institutional capital engagement
Med-Tech & Bio-Tools
Company Categories
MedTech & BioTools
Medical Devices
Implants
Therapeutic Devices
Wearables &
Monitoring
Connected
Care
Surgical & Interventional
Software as Med Device
AI & Agentic Tools
Diagnostics
Molecular Diagnostic
Imaging & Detection
Point-of-Care Systems
Research & Clinical Tools
Laboratory Automation
Drug
Discovery
Clinical
Workflow
Data &
Analysis
MedTech & BioTools
Common Challenges
CEOs In MedTech & Bio-Tools Face:
- Regulatory and clinical pathway clarity
- Market adoption and reimbursement complexity
- Manufacturing readiness
- Commercial execution discipline
- Investor readiness gaps
MedTech & Bio-Tools
2026-27 Sprint Calendar
CEOs progress through Four Execution Sprints:
-
Sprint #1 - Take Control May, 2026Leadership & company clarity
-
Sprint #2 - Build a Moat August, 2026Defensibility & regulatory realism
-
Sprint #3 - Capital Justification November, 2026Capital & milestone logic
-
Sprint #4 - Make It Scalable January, 2027Scale & strategic readiness
What CEOs Can
Accomplish In 4 Sprints
By the end of the program, CEOs typically achieve::
- Clear commercialization and adoption pathways
- Clarity on regulatory and reimbursement readiness
- Manufacturing and operational scale planning
- Capital strategies aligned to execution milestones
- Leadership discipline ready for scale
- Investor relationships formed through visible progress
MedTech & BioTools
Cohort Partners
